Ian F. Tannock - Publications

Affiliations: 
Medical Biophysics University of Toronto, Toronto, ON, Canada 
Area:
Oncology, Cell Biology

358 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Elimova E, Moignard S, Li X, Yu M, Xu W, Seruga B, Tannock IF. Updating Reports of Phase 3 Clinical Trials for Cancer. Jama Oncology. PMID 33538777 DOI: 10.1001/jamaoncol.2020.6968  0.88
2020 Benjamin DM, Mandel DR, Barnes T, Krzyzanowska MK, Leighl N, Tannock IF, Kimmelman J. Can Oncologists Predict the Efficacy of Treatments in Randomized Trials? The Oncologist. PMID 32936509 DOI: 10.1634/Theoncologist.2020-0054  0.36
2020 Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, ... Tannock IF, et al. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. Jnci Cancer Spectrum. 4: pkaa003. PMID 32368717 DOI: 10.1093/jncics/pkaa003  0.44
2020 Templeton AJ, Amir E, Tannock IF. Informative censoring - a neglected cause of bias in oncology trials. Nature Reviews. Clinical Oncology. PMID 32273582 DOI: 10.1038/S41571-020-0368-0  1
2020 Templeton AJ, Booth CM, Tannock IF. Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902035. PMID 32160103 DOI: 10.1200/JCO.19.02035  0.84
2019 Robbrecht DG, Delanoy N, Tannock IF, Tombal B, Eisenberger M, Fizazi K, Sartor O, Mercier F, Oudard S, de Wit R. Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. European Journal of Cancer (Oxford, England : 1990). PMID 31837907 DOI: 10.1016/j.ejca.2019.10.029  0.36
2019 Del Paggio JC, Tannock IF. A critique of the fragility index - Authors' reply. The Lancet. Oncology. 20: e554. PMID 31578996 DOI: 10.1016/S1470-2045(19)30580-7  0.36
2019 Del Paggio JC, Tannock IF. The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. The Lancet. Oncology. PMID 31296490 DOI: 10.1016/S1470-2045(19)30338-9  0.36
2019 Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. European Urology Oncology. 2: 448-455. PMID 31277782 DOI: 10.1016/J.Euo.2018.10.003  1
2019 Vera-Badillo FE, Tannock IF, Booth CM. Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802257. PMID 31260641 DOI: 10.1200/JCO.18.02257  0.8
2019 Hansen AR, Tannock IF, Templeton A, Chen E, Evans A, Knox J, Prawira A, Sridhar SS, Tan S, Vera-Badillo F, Wang L, Wouters BG, Joshua AM. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). The Oncologist. PMID 30952818 DOI: 10.1634/theoncologist.2018-0621  0.84
2018 Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, ... ... Tannock IF, et al. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801279. PMID 30576268 DOI: 10.1200/JCO.18.01279  0.44
2018 Vardy JL, Dhillon HM, Pond GR, Renton C, Clarke SJ, Tannock IF. Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. Esmo Open. 3: e000302. PMID 29531839 DOI: 10.1136/esmoopen-2017-000302  0.76
2018 Niraula S, Templeton AJ, Vera-Badillo F, Dodd A, Nugent Z, Joshua AM, Tannock IF. Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer. Future Science Oa. 4: FSO253. PMID 29255625 DOI: 10.4155/fsoa-2017-0094  0.84
2017 Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treatment Reviews. 62: 1-8. PMID 29126017 DOI: 10.1016/J.Ctrv.2017.10.008  1
2017 Winocur G, Berman H, Nguyen M, Binns MA, Henkelman M, van Eede M, Piquette-Miller M, Sekeres MJ, Wojtowicz JM, Yu J, Zhang H, Tannock IF. Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer. Neuroscience. PMID 29113931 DOI: 10.1016/J.Neuroscience.2017.10.048  0.32
2017 Dhillon HM, Tannock IF, Pond GR, Renton C, Rourke SB, Vardy JL. Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. Journal of Cancer Survivorship : Research and Practice. PMID 29080061 DOI: 10.1007/s11764-017-0656-6  0.76
2017 Pezaro CJ, Omlin A, Mastris K, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, ... ... Tannock I, et al. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 1692-1694. PMID 28838209 DOI: 10.1093/annonc/mdx312  0.44
2017 Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, ... ... Tannock I, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology. PMID 28655541 DOI: 10.1016/J.Eururo.2017.06.002  0.44
2017 Del Paggio JC, Sullivan R, Schrag D, Hopman WM, Azariah B, Pramesh CS, Tannock IF, Booth CM. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. The Lancet. Oncology. PMID 28583794 DOI: 10.1016/S1470-2045(17)30415-1  0.52
2017 Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, Dodd A, Crawley A, Tannock IF. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging and Behavior. PMID 28466438 DOI: 10.1007/s11682-017-9728-5  0.52
2017 Tan Q, Joshua AM, Wang M, Bristow RG, Wouters BG, Allen CJ, Tannock IF. Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity. Cancer Chemotherapy and Pharmacology. PMID 28378028 DOI: 10.1007/S00280-017-3298-5  0.44
2016 Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F. Relevance of randomised controlled trials in oncology. The Lancet. Oncology. 17: e560-e567. PMID 27924754 DOI: 10.1016/S1470-2045(16)30572-1  1
2016 Del Paggio JC, Azariah B, Sullivan R, Hopman WM, James FV, Roshni S, Tannock IF, Booth CM. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit? Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27742650 DOI: 10.1093/annonc/mdw538  0.52
2016 Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Templeton AJ, Seruga B, Amir E, Tannock IF. Honorary and ghost authorship in reports of randomised clinical trials in oncology. European Journal of Cancer (Oxford, England : 1990). 66: 1-8. PMID 27500368 DOI: 10.1016/J.Ejca.2016.06.023  1
2016 Vardy JL, Dhillon HM, Pond GR, Renton C, Dodd A, Zhang H, Clarke SJ, Tannock IF. Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27443634 DOI: 10.1093/annonc/mdw252  0.76
2016 Winocur G, Wojtowicz JM, Merkley CM, Tannock IF. Environmental Enrichment Protects Against Cognitive Impairment Following Chemotherapy in an Animal Model. Behavioral Neuroscience. PMID 27337062 DOI: 10.1037/Bne0000155  1
2016 Seruga B, Templeton AJ, Badillo FE, Ocana A, Amir E, Tannock IF. Under-reporting of harm in clinical trials. The Lancet. Oncology. 17: e209-19. PMID 27301048 DOI: 10.1016/S1470-2045(16)00152-2  1
2016 Tannock IF. The five Rs of chemotherapy. The Lancet. Oncology. 17: 703-5. PMID 27299264 DOI: 10.1016/S1470-2045(16)00103-0  1
2016 Tan Q, Wang M, Yu M, Zhang J, Bristow RG, Hill RP, Tannock IF. Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors. Neoplasia (New York, N.Y.). 18: 347-55. PMID 27292024 DOI: 10.1016/J.Neo.2016.04.003  0.56
2016 Ocana A, Amir E, Tannock IF. Toward Value-Based Pricing to Boost Cancer Research and Innovation. Cancer Research. 76: 3127-9. PMID 27197164 DOI: 10.1158/0008-5472.Can-15-3179  1
2016 Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF. Bias in reporting of randomised clinical trials in oncology. European Journal of Cancer (Oxford, England : 1990). 61: 29-35. PMID 27151552 DOI: 10.1016/J.Ejca.2016.03.066  1
2016 Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, ... ... Tannock IF, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27141017 DOI: 10.1093/Annonc/Mdw180  0.44
2016 Yao C, Rich JB, Tannock IF, Seruga B, Tirona K, Bernstein LJ. Pretreatment Differences in Intraindividual Variability in Reaction Time between Women Diagnosed with Breast Cancer and Healthy Controls. Journal of the International Neuropsychological Society : Jins. 1-10. PMID 26960672 DOI: 10.1017/S1355617716000126  1
2016 Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, ... ... Tannock IF, et al. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26951312 DOI: 10.1200/Jco.2015.65.7270  1
2016 Niraula S, Templeton AJ, Vera-Badillo FE, Joshua AM, Sridhar SS, Cheung PW, Yip PM, Dodd A, Nugent Z, Tannock IF. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer. The Prostate. 76: 235-42. PMID 26768279 DOI: 10.1002/Pros.23117  0.84
2016 Tannock IF, Sternberg CN. Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy Annals of Oncology. 27: 545-546. PMID 26659397 DOI: 10.1093/annonc/mdv600  1
2015 Niraula S, Tannock IF. Harms of Intermittent vs Continuous Androgen-Deprivation Therapy for Prostate Cancer. Jama Oncology. 1-2. PMID 26720183 DOI: 10.1001/jamaoncol.2015.4682  1
2015 Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF. Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527785 DOI: 10.1200/JCO.2015.63.0905  1
2015 Seruga B, Ocana A, Amir E, Tannock IF. Failures in Phase III: Causes and Consequences. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4552-60. PMID 26473191 DOI: 10.1158/1078-0432.Ccr-15-0124  1
2015 Tan Q, Saggar JK, Yu M, Wang M, Tannock IF. Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them. Cancer Journal (Sudbury, Mass.). 21: 254-62. PMID 26222076 DOI: 10.1097/Ppo.0000000000000131  1
2015 Yu M, Lee C, Wang M, Tannock IF. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. Cancer Science. 106: 1438-47. PMID 26212113 DOI: 10.1111/cas.12756  1
2015 Booth CM, Tannock IF. Benefits of Adjuvant Chemotherapy for Bladder Cancer. Jama Oncology. 1: 727-8. PMID 26181353 DOI: 10.1001/jamaoncol.2015.1210  1
2015 Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. Journal of Clinical Pathology. PMID 26076967 DOI: 10.1136/Jclinpath-2015-203012  1
2015 Stapleton S, Milosevic M, Tannock IF, Allen C, Jaffray DA. The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 211: 163-170. PMID 26070245 DOI: 10.1016/J.Jconrel.2015.06.008  1
2015 Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1660-7. PMID 26002607 DOI: 10.1093/annonc/mdv245  1
2015 Fung AS, Lee C, Yu M, Tannock IF. The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts. Bmc Cancer. 15: 112. PMID 25884767 DOI: 10.1186/s12885-015-1091-6  0.56
2015 Alibhai SM, Breunis H, Timilshina N, Naglie G, Tannock I, Krahn M, Warde P, Fleshner NE, Canning SD, Tomlinson G. Long-term impact of androgen-deprivation therapy on physical function and quality of life. Cancer. 121: 2350-7. PMID 25809861 DOI: 10.1002/Cncr.29355  1
2015 Templeton AJ, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond GR, Tannock IF. Influence of censoring on conclusions of trials for women with metastatic breast cancer. European Journal of Cancer (Oxford, England : 1990). 51: 721-4. PMID 25728257 DOI: 10.1016/J.Ejca.2014.12.016  1
2015 Saggar JK, Tannock IF. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2107-14. PMID 25677696 DOI: 10.1158/1078-0432.Ccr-14-2298  1
2015 Leveridge MJ, Siemens DR, Mackillop WJ, Peng Y, Tannock IF, Berman DM, Booth CM. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. Urology. 85: 791-8. PMID 25661830 DOI: 10.1016/J.Urology.2014.12.027  1
2015 Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Kanga N, Zhang JY, Chen X, Wouters BG, Tannock IF. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. British Journal of Cancer. 112: 832-40. PMID 25647012 DOI: 10.1038/bjc.2015.17  1
2015 Wilson MK, Collyar D, Chingos DT, Friedlander M, Ho TW, Karakasis K, Kaye S, Parmar MK, Sydes MR, Tannock IF, Oza AM. Outcomes and endpoints in cancer trials: bridging the divide. The Lancet. Oncology. 16: e43-52. PMID 25638556 DOI: 10.1016/S1470-2045(14)70380-8  1
2015 Leibowitz-Amit R, Khoja L, Tannock IF, Joshua AM. Choosing a better end point for trials of bone-protective agents. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 26: 1032-3. PMID 25632065 DOI: 10.1093/annonc/mdv039  0.44
2015 Winocur G, Wojtowicz JM, Tannock IF. Memory loss in chemotherapy-treated rats is exacerbated in high-interference conditions and related to suppression of hippocampal neurogenesis. Behavioural Brain Research. 281: 239-44. PMID 25529185 DOI: 10.1016/J.Bbr.2014.12.028  1
2015 van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 743-9. PMID 25515657 DOI: 10.1093/Annonc/Mdu569  1
2015 Tannock IF. Cancer: Resistance through repopulation. Nature. 517: 152-3. PMID 25470047 DOI: 10.1038/nature14075  1
2015 Leibowitz-Amit R, Templeton AJ, Alibhai SM, Knox JJ, Sridhar SS, Tannock IF, Joshua AM. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. Journal of Geriatric Oncology. 6: 23-8. PMID 25301537 DOI: 10.1016/j.jgo.2014.09.183  1
2015 Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. European Urology. 67: 740-9. PMID 24882670 DOI: 10.1016/J.Eururo.2014.05.010  1
2015 Tannock I, Toi M, Chow LW. Organisation for oncology and translational research newsletter International Journal of Biological Markers. 30: e152-e153. DOI: 10.5301/Jbm.5000152  1
2015 Niraula S, Templeton AJ, Vera-Badillo FE, Joshua AM, Sridhar SS, Cheung PW, Yip PM, Dodd A, Nugent Z, Tannock IF. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer Prostate. DOI: 10.1002/pros.23117  1
2014 van Soest RJ, Templeton AJ, Eisenberger M, Mercier F, Tannock IF, De Wit R. 786PTHE IMPACT OF THE DERIVED NEUTROPHIL TO LYMPHOCYTE RATIO AND DURATION OF INITIAL ANDROGEN DEPRIVATION THERAPY (ADT) ON SURVIVAL OF MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING FIRST-LINE CHEMOTHERAPY: DATA FROM TWO RANDOMIZED PHASE III TRIALS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv271-iv272. PMID 28170512 DOI: 10.1093/annonc/mdu336.34  0.84
2014 Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaud P. Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 4120-6. PMID 25403215 DOI: 10.1200/Jco.2014.56.7503  1
2014 Shao T, Wang L, Templeton AJ, Jang R, Vera-Badillo FW, McNamara MG, Margolis M, Kim TK, Sinaei M, Shoushtari H, Tannock IF. Use and misuse of waterfall plots. Journal of the National Cancer Institute. 106. PMID 25359866 DOI: 10.1093/Jnci/Dju331  1
2014 Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3634-42. PMID 25267757 DOI: 10.1200/Jco.2014.55.8437  1
2014 Vardy J, Dhillon HM, Pond GR, Rourke SB, Xu W, Dodd A, Renton C, Park A, Bekele T, Ringash J, Zhang H, Burkes R, Clarke SJ, Tannock IF. Cognitive function and fatigue after diagnosis of colorectal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2404-12. PMID 25214544 DOI: 10.1093/annonc/mdu448  0.76
2014 Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, Douglas S, Wang L, Siu LL, Tannock IF, Bedard PL. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Investigational New Drugs. 32: 1269-77. PMID 25213162 DOI: 10.1007/S10637-014-0159-5  1
2014 Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah JA, Templeton AJ, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. The Prostate. 74: 1462-4. PMID 25111736 DOI: 10.1002/Pros.22861  0.84
2014 Vera-Badillo FE, Ocana A, Templeton AJ, Tibau A, Amir E, Tannock IF. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3197. PMID 25092777 DOI: 10.1200/Jco.2014.56.2447  1
2014 Tannock IF, Pond GR. Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer Annals of Oncology. 25: 2096. PMID 25085505 DOI: 10.1093/annonc/mdu371  1
2014 Leibowitz-Amit R, Seah JA, Atenafu EG, Templeton AJ, Vera-Badillo FE, Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. European Journal of Cancer (Oxford, England : 1990). 50: 2399-407. PMID 25042152 DOI: 10.1016/j.ejca.2014.06.004  0.84
2014 Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 120: 3346-52. PMID 24995769 DOI: 10.1002/Cncr.28890  1
2014 Vera-Badillo FE, Napoleone M, Ocana A, Templeton AJ, Seruga B, Al-Mubarak M, AlHashem H, Tannock IF, Amir E. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 146: 235-44. PMID 24928527 DOI: 10.1200/Jco.2014.32.15_Suppl.546  1
2014 Booth CM, Siemens DR, Peng Y, Tannock IF, Mackillop WJ. Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice Annals of Oncology. 25: 1783-1788. PMID 24915872 DOI: 10.1093/Annonc/Mdu204  1
2014 Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the National Cancer Institute. 106: dju124. PMID 24875653 DOI: 10.1093/Jnci/Dju124  1
2014 Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1204-12. PMID 24793958 DOI: 10.1158/1055-9965.Epi-14-0146  1
2014 Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, Berman DM, Mackillop WJ. Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer. 120: 1630-8. PMID 24733278 DOI: 10.1002/Cncr.28510  1
2014 Bernstein LJ, Catton PA, Tannock IF. Intra-individual variability in women with breast cancer. Journal of the International Neuropsychological Society : Jins. 20: 380-90. PMID 24621519 DOI: 10.1017/S1355617714000125  1
2014 Tannock IF. Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. European Urology. 65: 846-7. PMID 24559903 DOI: 10.1016/j.eururo.2013.12.033  1
2014 Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. British Journal of Cancer. 110: 551-5. PMID 24495873 DOI: 10.1038/bjc.2013.725  1
2014 Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, Eisenberger MA, Tannock IF. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. Journal of Geriatric Oncology. 5: 119-26. PMID 24495703 DOI: 10.1016/J.Jgo.2013.12.001  1
2014 Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, de Bono JS, Joshua AM. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 657-62. PMID 24458472 DOI: 10.1093/Annonc/Mdt581  1
2014 Winocur G, Wojtowicz JM, Huang J, Tannock IF. Physical exercise prevents suppression of hippocampal neurogenesis and reduces cognitive impairment in chemotherapy-treated rats. Psychopharmacology. 231: 2311-20. PMID 24343419 DOI: 10.1007/S00213-013-3394-0  1
2014 Saggar JK, Tannock IF. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. International Journal of Cancer. 134: 2726-34. PMID 24338277 DOI: 10.1002/Ijc.28595  1
2014 Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute. 106: djt319. PMID 24273215 DOI: 10.1093/Jnci/Djt319  1
2014 Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. European Urology. 65: 3-6. PMID 24120464 DOI: 10.1016/J.Eururo.2013.09.024  0.76
2014 van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. European Urology. 66: 330-6. PMID 23957945 DOI: 10.1016/J.Eururo.2013.08.007  0.36
2013 de Morrée E, Shen L, Tannock I, Eisenberger MA, De Wit R. The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 44. PMID 28137000 DOI: 10.1200/Jco.2013.31.6_Suppl.44  0.36
2013 Wang L, Vera-Badillo F, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore MJ, Sridhar SS, Joshua AM, Tannock I. From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 125. PMID 28136799 DOI: 10.1200/Jco.2013.31.6_Suppl.125  0.84
2013 Swami N, Krzyzanowska MK, Leighl NB, Oza AM, Moore MJ, Rodin G, Tannock I, Zimmermann C. Patients' perceptions of early palliative oncology care: A qualitative analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 138. PMID 28136412 DOI: 10.1200/Jco.2013.31.31_Suppl.138  0.36
2013 Patel KJ, Lee C, Tan Q, Tannock IF. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6766-76. PMID 24141627 DOI: 10.1158/1078-0432.CCR-13-0128  1
2013 Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Razak AR. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4260-7. PMID 24127441 DOI: 10.1200/Jco.2012.47.4957  1
2013 Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2972-7. PMID 24126362 DOI: 10.1093/Annonc/Mdt397  1
2013 Niraula S, Le LW, Tannock IF. Reply to J. Zhu et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4025. PMID 24062409 DOI: 10.1200/JCO.2013.52.4546  1
2013 Walter T, Wang L, Chuk K, Ng P, Tannock IF, Krzyzanowska MK. Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 20: 249-256. PMID 24022406 DOI: 10.1177/1078155213501100  0.36
2013 Vera-Badillo FE, Tannock IF. Spin and bias: The tip of the iceberg Annals of Oncology. 24: 1949-1950. PMID 23961553 DOI: 10.1093/annonc/mdt211  1
2013 Booth CM, Tannock IF. Evaluation of treatment benefit: randomized controlled trials and population-based observational research. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3298-9. PMID 23940222 DOI: 10.1200/JCO.2013.51.5023  1
2013 Ocana A, Amir E, Vera-Badillo F, Seruga B, Tannock IF. Phase III trials of targeted anticancer therapies: redesigning the concept. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4931-40. PMID 23881926 DOI: 10.1158/1078-0432.Ccr-13-1222  1
2013 Fung AS, Yu M, Ye QJ, Tannock IF. Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor. Cancer Chemotherapy and Pharmacology. 72: 585-95. PMID 23851981 DOI: 10.1007/S00280-013-2229-3  0.56
2013 Saggar JK, Yu M, Tan Q, Tannock IF. The tumor microenvironment and strategies to improve drug distribution. Frontiers in Oncology. 3: 154. PMID 23772420 DOI: 10.3389/Fonc.2013.00154  1
2013 Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. The Lancet. Oncology. 14: 760-8. PMID 23742877 DOI: 10.1016/S1470-2045(13)70184-0  0.36
2013 Patel KJ, Trédan O, Tannock IF. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemotherapy and Pharmacology. 72: 127-38. PMID 23680920 DOI: 10.1007/s00280-013-2176-z  1
2013 Niraula S, Pond G, de Wit R, Eisenberger M, Tannock IF, Joshua AM. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 7: E74-81. PMID 23671512 DOI: 10.1200/Jco.2010.28.15_Suppl.4686  0.84
2013 Lun G, Atenafu EG, Knox JJ, Sridhar SS, Tannock IF, Joshua AM. Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: a pilot project at a Canadian cancer center. Clinical Genitourinary Cancer. 11: 342-345.e1. PMID 23665134 DOI: 10.1016/j.clgc.2013.04.008  0.56
2013 Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2029-36. PMID 23630216 DOI: 10.1200/Jco.2012.46.5492  1
2013 Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, Fleshner N, Krahn MD, Naglie G, Tannock IF, Tomlinson G, Warde P, Duff Canning S, Cheung AM. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of the Usa. 24: 2571-9. PMID 23563932 DOI: 10.1007/S00198-013-2343-4  1
2013 Caldas C, Tannock IF. Breast cancer: Tamoxifen--when more might be better. Nature Reviews. Clinical Oncology. 10: 125-6. PMID 23380999 DOI: 10.1038/Nrclinonc.2013.17  1
2013 Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Investigational New Drugs. 31: 1008-15. PMID 23354849 DOI: 10.1007/s10637-013-9931-1  1
2013 Saggar JK, Fung AS, Patel KJ, Tannock IF. Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Molecular Cancer Therapeutics. 12: 542-52. PMID 23348047 DOI: 10.1158/1535-7163.Mct-12-0967  1
2013 Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1238-44. PMID 23303339 DOI: 10.1093/Annonc/Mds636  1
2013 Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Reviews. 32: 211-27. PMID 23093326 DOI: 10.1007/S10555-012-9402-8  1
2013 Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. American Journal of Clinical Oncology. 36: 436-42. PMID 22781385 DOI: 10.1097/Coc.0B013E3182568F7A  1
2012 Staruch RM, Ganguly M, Tannock IF, Hynynen K, Chopra R. Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. International Journal of Hyperthermia : the Official Journal of European Society For Hyperthermic Oncology, North American Hyperthermia Group. 28: 776-87. PMID 23153219 DOI: 10.3109/02656736.2012.736670  1
2012 Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, Amir E. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3012-9. PMID 22802313 DOI: 10.1200/Jco.2011.40.3824  1
2012 Seruga B, Pond GR, Hertz PC, Amir E, Ocana A, Tannock IF. Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2977-82. PMID 22734009 DOI: 10.1093/Annonc/Mds174  1
2012 Grantab RH, Tannock IF. Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. Bmc Cancer. 12: 214. PMID 22672469 DOI: 10.1186/1471-2407-12-214  1
2012 Fung AS, Jonkman J, Tannock IF. Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel. Neoplasia (New York, N.Y.). 14: 324-34. PMID 22577347 DOI: 10.1593/Neo.12346  1
2012 Winocur G, Henkelman M, Wojtowicz JM, Zhang H, Binns MA, Tannock IF. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3112-21. PMID 22467680 DOI: 10.1158/1078-0432.Ccr-12-0060  1
2012 Yu M, Tannock IF. Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell. 21: 327-9. PMID 22439929 DOI: 10.1016/j.ccr.2012.03.002  0.56
2012 Ocana A, Amir E, Yeung C, Seruga B, Tannock IF. How valid are claims for synergy in published clinical studies? Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2161-6. PMID 22314859 DOI: 10.1093/Annonc/Mdr608  1
2012 Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, Sridhar SS, Knox JJ, Day JR, Groskopf J, Joshua AM. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. Bju International. 110: 840-5. PMID 22313860 DOI: 10.1111/j.1464-410X.2011.10922.x  0.56
2012 Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer Journal of Clinical Oncology. 30: 587-592. PMID 22124102 DOI: 10.1200/Jco.2010.33.5232  1
2012 Amir E, Seruga B, Kwong R, Tannock IF, Ocaña A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? European Journal of Cancer (Oxford, England : 1990). 48: 385-8. PMID 22115991 DOI: 10.1016/J.Ejca.2011.10.028  1
2012 Kim S, Bordeleau L, Tannock IF, Rotstein C. A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 18: 293-5. PMID 21911478 DOI: 10.1177/1078155211412991  1
2012 Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Sonpavde G. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European Urology. 61: 363-9. PMID 21715086 DOI: 10.1016/J.Eururo.2011.06.034  1
2012 Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, Tannock IF. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology. 30: 607-13. PMID 20888271 DOI: 10.1016/J.Urolonc.2010.07.002  0.76
2011 Booth CM, Siemens DR, Tannock I, Peng Y, Li G, Mackillop WJ. Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4644. PMID 28023930 DOI: 10.1200/Jco.2011.29.15_Suppl.4644  0.52
2011 Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Berry WR, De Wit R, Eisenberger MA, Tannock I, Sonpavde G. Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4582. PMID 28023307 DOI: 10.1200/Jco.2011.29.15_Suppl.4582  0.76
2011 Vardy JL, Pond GR, Dodd A, Warr D, Seruga B, Clemons MJ, Bordeleau L, Tannock I. A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9020. PMID 28021684 DOI: 10.1200/Jco.2011.29.15_Suppl.9020  0.88
2011 Sonpavde G, Pond GR, Berry WR, De Wit R, Eisenberger MA, Tannock I, Armstrong AJ. Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 118. PMID 27968667 DOI: 10.1200/jco.2011.29.7_suppl.118  0.76
2011 Niraula S, Emmeneger U, Adams L, Tannock I, Sridhar SS, Knox JJ, Day JR, Manthe J, Groskopf J, Joshua AM. Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 59. PMID 27968402 DOI: 10.1200/Jco.2011.29.7_Suppl.59  0.84
2011 Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, et al. Delivering affordable cancer care in high-income countries. The Lancet. Oncology. 12: 933-80. PMID 21958503 DOI: 10.1016/S1470-2045(11)70141-3  1
2011 Rothenstein JM, Tomlinson G, Tannock IF, Detsky AS. Company stock prices before and after public announcements related to oncology drugs. Journal of the National Cancer Institute. 103: 1507-12. PMID 21949081 DOI: 10.1093/Jnci/Djr338  1
2011 Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3686-94. PMID 21844499 DOI: 10.1200/Jco.2010.34.3996  1
2011 Winocur G, Binns MA, Tannock I. Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model. Neuropharmacology. 61: 1222-8. PMID 21803055 DOI: 10.1016/J.Neuropharm.2011.07.013  1
2011 Tam VC, Tannock IF, Massey C, Rauw J, Krzyzanowska MK. Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3133-9. PMID 21747079 DOI: 10.1200/Jco.2010.33.3922  1
2011 Tagami T, Foltz WD, Ernsting MJ, Lee CM, Tannock IF, May JP, Li SD. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials. 32: 6570-8. PMID 21641639 DOI: 10.1016/J.Biomaterials.2011.05.029  1
2011 Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2543-9. PMID 21606435 DOI: 10.1200/Jco.2011.35.2393  1
2011 Niraula S, Tannock IF. Broadening horizons in medical management of prostate cancer. Acta Oncologica (Stockholm, Sweden). 50: 141-7. PMID 21604955 DOI: 10.3109/0284186X.2010.524936  1
2011 Beltran H, Beer TM, Carducci MA, De Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: Efficacy and safety European Urology. 60: 279-290. PMID 21592649 DOI: 10.1016/J.Eururo.2011.04.038  1
2011 Petit T, Dufour P, Tannock I. A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. Endocrine-Related Cancer. 18: R79-89. PMID 21502311 DOI: 10.1530/ERC-10-0162  1
2011 Tannock IF. 10-year analysis of the ATAC trial: wrong conclusion? The Lancet. Oncology. 12: 216-7; author reply . PMID 21376288 DOI: 10.1016/S1470-2045(11)70049-3  1
2011 Sonpavde G, Pond GR, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer. 117: 3963-71. PMID 21365623 DOI: 10.1200/Jco.2011.29.7_Suppl.118  0.76
2011 Ocaña A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 254-6. PMID 21149670 DOI: 10.1200/Jco.2010.32.0275  1
2011 Ocana A, Pandiella A, Siu LL, Tannock IF. Preclinical development of molecular-targeted agents for cancer. Nature Reviews. Clinical Oncology. 8: 200-9. PMID 21135887 DOI: 10.1038/Nrclinonc.2010.194  0.88
2011 Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 174-85. PMID 21135271 DOI: 10.1200/Jco.2010.31.9624  1
2011 Ocana A, Tannock IF. When are "positive" clinical trials in oncology truly positive? Journal of the National Cancer Institute. 103: 16-20. PMID 21131576 DOI: 10.1093/Jnci/Djq463  1
2011 Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nature Reviews. Clinical Oncology. 8: 12-23. PMID 20859283 DOI: 10.1038/Nrclinonc.2010.136  1
2011 Zimmermann C, Burman D, Swami N, Krzyzanowska MK, Leighl N, Moore M, Rodin G, Tannock I. Determinants of quality of life in patients with advanced cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 19: 621-9. PMID 20349353 DOI: 10.1007/S00520-010-0866-1  1
2010 Alibhai SMH, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Canning SD, Klotz L, Naglie G. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer Journal of Clinical Oncology. 28: 5038-5045. PMID 21041715 DOI: 10.1200/Jco.2010.29.8091  1
2010 Alibhai SMH, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, Naglie G, Tomlinson G, Fleshner N, Krahn M, Warde P, Canning SD. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer Journal of Clinical Oncology. 28: 5030-5037. PMID 21041708 DOI: 10.1200/Jco.2010.30.8742  1
2010 Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4247-54. PMID 20733135 DOI: 10.1200/Jco.2009.26.8771  0.56
2010 Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. Bmc Cancer. 10: 255. PMID 20525277 DOI: 10.1186/1471-2407-10-255  1
2010 Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 203-11. PMID 20008841 DOI: 10.1158/1078-0432.Ccr-09-2514  1
2010 Seruga B, Hertz PC, Le LW, Tannock IF. Global drug development in cancer: a cross-sectional study of clinical trial registries. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 895-900. PMID 19815650 DOI: 10.1200/Jco.2009.27.15_Suppl.2520  0.88
2010 Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. The American Journal of Hospice & Palliative Care. 27: 106-10. PMID 19776373 DOI: 10.1177/1049909109345685  1
2009 Amir E, Tannock IF. Prostate cancer: Androgen deprivation therapy and bone loss. Nature Reviews. Urology. 6: 642-4. PMID 19956194 DOI: 10.1038/Nrurol.2009.218  1
2009 Patel KJ, Tannock IF. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. Bmc Cancer. 9: 356. PMID 19807929 DOI: 10.1186/1471-2407-9-356  1
2009 Fung AS, Wu L, Tannock IF. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5389-95. PMID 19706800 DOI: 10.1158/1078-0432.Ccr-08-3007  1
2009 Tannock IF. Effects of food on bioavailability of lapatinib: useful data, wrong conclusion. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e42; author reply e4. PMID 19581528 DOI: 10.1200/Jco.2009.23.8899  1
2009 Amir E, Seruga B, Freedman O, Tannock I. Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1919; author reply 1. PMID 19255302 DOI: 10.1200/Jco.2008.21.2951  1
2009 Berthold DR, Gulamhusein A, Jackson JI, Tannock IF. The transition from phase II to phase III studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1150-1. PMID 19171698 DOI: 10.1200/Jco.2008.21.1938  1
2009 Seruga B, Tannock IF. Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 840-2. PMID 19139426 DOI: 10.1200/Jco.2008.19.5594  1
2009 Armstrong AJ, Halabi S, de Wit R, Tannock IF, Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer Prostate Cancer and Prostatic Diseases. 12: 88-93. PMID 18574490 DOI: 10.1200/Jco.2008.26.15_Suppl.5074  1
2008 Joshua AM, Broom R, Milosevic M, Jewett M, Evans A, Asa S, Tannock IF, Knox JJ. Rationale and evidence for the use of sunitnib to treat patients with malignant paraganglioma/pheochromocytoma (MPP). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14681. PMID 27949422 DOI: 10.1200/Jco.2008.26.15_Suppl.14681  0.56
2008 Vardy JL, Xu W, Booth CM, Park A, Dodd A, Rourke S, Dhillon H, Clarke SJ, Wagner L, Tannock IF. Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 9520. PMID 27948228 DOI: 10.1200/Jco.2008.26.15_Suppl.9520  0.52
2008 Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of the randomized controlled trial in oncology over three decades. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5458-64. PMID 18955452 DOI: 10.1200/Jco.2008.16.5456  0.52
2008 Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nature Reviews. Cancer. 8: 887-99. PMID 18846100 DOI: 10.1038/nrc2507  0.88
2008 Seruga B, Tannock IF. The changing face of hormonal therapy for prostate cancer Annals of Oncology. 19. PMID 18790984 DOI: 10.1093/Annonc/Mdn477  1
2008 Seruga B, Tannock IF. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nature Clinical Practice. Oncology. 5: 574-6. PMID 18628739 DOI: 10.1038/Ncponc1180  1
2008 Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1749-53. PMID 18487550 DOI: 10.1093/Annonc/Mdn288  1
2008 Seruga B, Tannock IF. Mathematics in the realm of lapatinib: 500 + 500 = 1,500? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2940-2. PMID 18458041 DOI: 10.1200/Jco.2008.16.5282  1
2008 Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ. Sorafenib for metastatic renal cancer: the Princess Margaret experience. American Journal of Clinical Oncology. 31: 182-7. PMID 18391604 DOI: 10.1097/Coc.0B013E3181574084  1
2008 Kirkbride P, Tannock IF. Trials in palliative treatment--have the goal posts been moved? The Lancet. Oncology. 9: 186-7. PMID 18308238 DOI: 10.1016/S1470-2045(08)70041-X  1
2008 Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 242-5. PMID 18182665 DOI: 10.1200/JCO.2007.12.4008  1
2008 Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 623-9. PMID 17974553 DOI: 10.1093/annonc/mdm500  1
2008 Zimmermann C, Tannock IF, Rodin G. Studying the effectiveness of palliative care - Reply Jama - Journal of the American Medical Association. 300: 1023-1024. DOI: 10.1001/Jama.300.9.1023  1
2007 Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute. 99: 1441-54. PMID 17895480 DOI: 10.1093/jnci/djm135  1
2007 Joly F, Vardy J, Pintilie M, Tannock IF. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer Annals of Oncology. 18: 1935-1942. PMID 17698837 DOI: 10.1093/Annonc/Mdm121  1
2007 Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3482-7. PMID 17687153 DOI: 10.1200/Jco.2007.11.3670  1
2007 Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF, Gospodarowicz MK. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology. 25: 303-9. PMID 17628296 DOI: 10.1016/J.Urolonc.2006.09.015  1
2007 Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2455-63. PMID 17485710 DOI: 10.1200/Jco.2006.08.1604  1
2007 Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. Journal of the National Cancer Institute. 99: 592-600. PMID 17440160 DOI: 10.1093/Jnci/Djk130  0.36
2007 Berlin J, Bruinooge SS, Tannock IF. Ethics in oncology: consulting for the investment industry. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 444-6. PMID 17264341 DOI: 10.1200/Jco.2006.10.3036  1
2007 Krzyzanowska MK, Tannock IF, Lockwood G, Knox J, Moore M, Bjarnason GA. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 60: 135-41. PMID 17009033 DOI: 10.1007/s00280-006-0347-x  0.36
2007 Armstrong AJ, Garrett-Mayer E, Eisenberger M, Tannock I, De Wit R. In reply [12] Journal of Clinical Oncology. 25: 5674. DOI: 10.1200/Jco.2007.14.5383  1
2007 Berthold DR, Tannock IF. Hormone-resistant prostate cancer: New therapies needed Oncology. 21.  1
2006 Pentz RD, Joffe S, Emanuel EJ, Schnipper LE, Haskell CM, Tannock IF. ASCO core values. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5780-2. PMID 17179111 DOI: 10.1200/Jco.2006.08.5068  1
2006 Joly F, Alibhai SMH, Galica J, Park A, Yi QL, Wagner L, Tannock IF. Impact of Androgen Deprivation Therapy on Physical and Cognitive Function, as Well as Quality of Life of Patients With Nonmetastatic Prostate Cancer Journal of Urology. 176: 2443-2447. PMID 17085125 DOI: 10.1016/J.Juro.2006.07.151  1
2006 Duran I, Tannock IF. Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. Journal of General Internal Medicine. 21: C6-8. PMID 17026724 DOI: 10.1111/j.1525-1497.2006.00506.x  1
2006 Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacology, Biochemistry, and Behavior. 85: 66-75. PMID 16935324 DOI: 10.1016/J.Pbb.2006.07.010  1
2006 Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nature Reviews. Cancer. 6: 583-92. PMID 16862189 DOI: 10.1038/nrc1893  1
2006 Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. British Journal of Cancer. 94: 1011-5. PMID 16552437 DOI: 10.1200/Jco.2005.23.16_Suppl.8017  1
2006 Vardy J, Wong K, Yi QL, Park A, Maruff P, Wagner L, Tannock IF. Assessing cognitive function in cancer patients Supportive Care in Cancer. 14: 1111-1118. PMID 16538498 DOI: 10.1007/S00520-006-0037-6  1
2006 Brade AM, Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1020-2. PMID 16505418 DOI: 10.1200/Jco.2005.04.9676  1
2006 Lee CM, Tannock IF. Inhibition of endosomal sequestration of basic anticancer drugs: Influence on cytotoxicity and tissue penetration British Journal of Cancer. 94: 863-869. PMID 16495919 DOI: 10.1038/Sj.Bjc.6603010  1
2006 Berthold DR, Tannock IF. Are prostate cancer clinical trial enrollment criteria and endpoints appropriate? Nature Clinical Practice. Oncology. 3: 74-5. PMID 16462843 DOI: 10.1038/Ncponc0425  1
2006 Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Research. 66: 1033-9. PMID 16424039 DOI: 10.1158/0008-5472.Can-05-3077  1
2006 Mar Fan HG, Vardy J, Xu W, Tannock IF. In reply [2] Journal of Clinical Oncology. 24: 5171-5172. DOI: 10.1200/JCO.2006.08.6157  1
2006 Tannock IF. "Know your PSA": Not always good advice Cancer Forum. 30: 101-102.  1
2005 Roessner M, de Wit R, Tannock IF, Yateman N, Yao SL, Yver A, Eisenberger MA. Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4554. PMID 27946377 DOI: 10.1200/Jco.2005.23.16_Suppl.4554  0.36
2005 Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8782-8. PMID 16361566 DOI: 10.1158/1078-0432.Ccr-05-1664  1
2005 Wu L, Tannock IF. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8195-200. PMID 16299252 DOI: 10.1158/1078-0432.Ccr-05-1258  1
2005 Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8247-52. PMID 16278480 DOI: 10.1200/Jco.2005.03.1435  1
2005 Bahl M, Ennis M, Tannock IF, Hux JE, Pritchard KI, Koo J, Goodwin PJ. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Research and Treatment. 94: 135-44. PMID 16261412 DOI: 10.1007/S10549-005-6654-9  1
2005 Krzyzanowska MK, Tannock IF. Should screen-detected breast cancers be managed differently? Journal of the National Cancer Institute. 97: 1170-1171. PMID 16106016 DOI: 10.1093/Jnci/Dji246  1
2005 Meyskens FL, Hietanen P, Tannock IF. Talking to a patient. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4463-4. PMID 15994158 DOI: 10.1200/Jco.2005.04.002  1
2005 Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nature Reviews. Cancer. 5: 516-25. PMID 15965493 DOI: 10.1038/nrc1650  1
2005 Wong P, Lee C, Tannock IF. Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells Clinical Cancer Research. 11: 3553-3557. PMID 15867259 DOI: 10.1158/1078-0432.Ccr-04-2472  1
2005 Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts Cancer Research. 65: 2825-2831. PMID 15805283 DOI: 10.1158/0008-5472.Can-04-3137  1
2004 Eisenberger MA, De Wit R, Berry W, Bodrogi I, Pluzanska A, Chi K, Oudard S, Christine T, James N, Tannock I. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4. PMID 28014163 DOI: 10.1200/Jco.2004.22.14_Suppl.4  0.36
2004 Bahl M, Siu LL, Pond GR, Kim J, Tannock IF, Bayley A, Cummings B, Waldron J, Ringash J, O'Sullivan B. Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 5572. PMID 28014006 DOI: 10.1200/jco.2004.22.14_suppl.5572  0.76
2004 Chen EX, Tannock IF. Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: A case for more innovation Journal of the American Medical Association. 292: 2150-2151. PMID 15523076 DOI: 10.1001/Jama.292.17.2150  1
2004 Joly F, Tannock IF. Chemotherapy for patients with hormone-refractory prostate cancer Annals of Oncology. 15: 1582-1584. PMID 15520057 DOI: 10.1093/Annonc/Mdh445  1
2004 Bahl M, Siu LL, Pond GR, Kim J, Tannock IF, Bayley A, Cummings BJ, Waldron J, Ringash J, Chen EX, Gitterman L, Lemon B, O'Sullivan B. Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. International Journal of Radiation Oncology, Biology, Physics. 60: 1127-36. PMID 15519784 DOI: 10.1016/J.Ijrobp.2004.05.011  1
2004 Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine. 351: 1502-12. PMID 15470213 DOI: 10.1056/NEJMoa040720  1
2004 Vardy J, Tannock IF. Quality of cancer care Annals of Oncology. 15: 1001-1006. PMID 15205191 DOI: 10.1093/Annonc/Mdh275  1
2004 Canil CM, Tannock IF. Is there a role for chemotherapy in prostate cancer? British Journal of Cancer. 91: 1005-1011. PMID 15150548 DOI: 10.1038/sj.bjc.6601850  1
2004 Vallis KA, Tannock IF. Postoperative radiotherapy for breast cancer: Growing evidence for an impact on survival Journal of the National Cancer Institute. 96: 88-89. PMID 14734691 DOI: 10.1093/Jnci/Djh029  1
2003 Licun W, Tannock IF. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy Clinical Cancer Research. 9: 4614-4618. PMID 14555537  1
2003 Krzyzanowska MK, Pintilie M, Tannock IF. Factors Associated with Failure to Publish Large Randomized Trials Presented at an Oncology Meeting Journal of the American Medical Association. 290: 495-501. PMID 12876092 DOI: 10.1001/Jama.290.4.495  1
2003 Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil Cancer Research. 63: 2134-2138. PMID 12727830  1
2003 Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel R, Ruether JD, Siu LL, Jolivet J, McIntosh L, Seymour L, Moore MJ. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1524-9. PMID 12697876 DOI: 10.1200/Jco.2003.03.057  1
2003 Chvetzoff G, Tannock IF. Placebo effects in oncology Journal of the National Cancer Institute. 95: 19-29. PMID 12509397 DOI: 10.1093/Jnci/95.1.19  1
2003 Tannock IF. From evidence-based medicine to clinical practice: Not always straightforward European Journal of Cancer, Supplement. 1: 93-101. DOI: 10.1016/S1359-6349(03)90013-9  1
2002 Davis AJ, Tannock IF. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration Cancer Treatment and Research. 112: 1-26. PMID 12481709 DOI: 10.1007/978-1-4615-1173-1_1  1
2002 Juffs HG, Moore MJ, Tannock IF. The role of systemic chemothearapy in the management of muscle-invasive bladder cancer Lancet Oncology. 3: 738-747. PMID 12473515 DOI: 10.1016/S1470-2045(02)00930-0  1
2002 Lofters A, Juffs HG, Pond GR, Tannock IF. "PSA-ITIS": Knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer Journal of Urology. 168: 2516-2520. PMID 12441952 DOI: 10.1016/S0022-5347(05)64180-8  1
2002 Canil CM, Tannock IF. Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone? Journal of the National Cancer Institute. 94: 1422-1423. PMID 12359844 DOI: 10.1093/Jnci/94.19.1422  1
2002 Isaac N, Panzarella T, Lau A, Mayers C, Kirkbride P, Tannock IF, Vallis KA. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer. 95: 696-703. PMID 12209711 DOI: 10.1002/cncr.10744  1
2002 Wong P, Kleemann HW, Tannock IF. Cytostatic potential of novel agents that inhibit the regulation of intracellular pH British Journal of Cancer. 87: 238-245. PMID 12107849  1
2002 Canil CM, Tannock IF. Doctor's dilemma: Incorporating tumor markers into clinical decision-making Seminars in Oncology. 29: 286-293. PMID 12063682 DOI: 10.1053/sonc.2002.32904  1
2002 Tannock IF. Eradication of a disease: How we cured symptomless prostate cancer Lancet. 359: 1341-1342. PMID 11965297 DOI: 10.1016/S0140-6736(02)08278-8  1
2002 Juffs HG, Tannock IF. Screening trials are even more difficult than we thought they were Journal of the National Cancer Institute. 94: 156-157. PMID 11830599 DOI: 10.1093/Jnci/94.3.156  1
2001 Tannock IF. Tumor physiology and drug resistance Cancer and Metastasis Reviews. 20: 123-132. PMID 11831640 DOI: 10.1023/A:1013125027697  1
2001 Tannock IF. Removing the primary tumor after the cancer has spread New England Journal of Medicine. 345: 1699-1700. PMID 11759650 DOI: 10.1056/Nejm200112063452310  1
2001 Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma Cancer. 91: 2246-2257. PMID 11413512 DOI: 10.1002/1097-0142(20010615)91:12<2246::Aid-Cncr1255>3.0.Co;2-4  1
2001 Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance Annals of Oncology. 12: 23-27. PMID 11249045 DOI: 10.1023/A:1008389706725  1
2001 Baumann M, Bentzen SM, Doerr W, Joiner MC, Saunders M, Tannock IF, Thames HD. The translational research chain: is it delivering the goods? International Journal of Radiation Oncology, Biology, Physics. 49: 345-51. PMID 11173127 DOI: 10.1016/S0360-3016(00)01483-8  1
2001 Tannock IF. Collaborative Clinical trials: Quality or quantity? International Journal of Radiation Oncology Biology Physics. 49: 339-343. PMID 11173126 DOI: 10.1016/S0360-3016(00)01500-5  1
2001 Cowan DSM, Tannock IF. Factors that influence the penetration of methotrexate through solid tissue International Journal of Cancer. 91: 120-125. PMID 11149410 DOI: 10.1002/1097-0215(20010101)91:1<120::Aid-Ijc1021>3.0.Co;2-Y  1
2001 Tannock IF, Lee C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs British Journal of Cancer. 84: 100-105. PMID 11139321 DOI: 10.1054/Bjoc.2000.1538  1
2001 Tannock IF. Management of metastatic prostate cancer Journal of B.U.On.. 6: 227-230.  1
2000 Davis AJ, Tannock IF. Repopulation of tumour cells between cycles of chemotherapy: A neglected factor Lancet Oncology. 1: 86-93. PMID 11905673 DOI: 10.1016/S1470-2045(00)00019-X  1
2000 Wilson KA, Dowling AJ, Abdolell M, Tannock IF. Perception of quality of life by patients, partners and treating physicians Quality of Life Research. 9: 1041-1052. PMID 11332225 DOI: 10.1023/A:1016647407161  1
2000 Tannock IF. Commentary on 'Cytoreduction nephrectomy in metastatic renal cancer: The results of southwest oncology group trial 8949' Journal of Clinical Oncology. 18. PMID 11060324  1
2000 Tannock IF. Quality of life issues related to organ sparing Radiology and Oncology. 34: 275-279.  1
2000 Siu LL, Tannock IF. The Ali/Al-Sarraf article reviewed Oncology. 14: 1237-1238.  1
1999 Adachi E, Tannock IF. The effects of vasodilating drugs on pH in tumors Oncology Research. 11: 179-185. PMID 10566616  1
1999 Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third- generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients Journal of Clinical Oncology. 17: 52-63. PMID 10458218 DOI: 10.1200/JCO.1999.17.1.52  1
1999 McLachlan SA, Pintilie M, Tannock IF. Third line chemotherapy in patients with metastatic breast cancer: An evaluation of quality of life and cost Breast Cancer Research and Treatment. 54: 213-223. PMID 10445420 DOI: 10.1023/A:1006123721205  1
1999 Sagar SM, Warr DG, Tannock IF. Alternative views on alternative therapies (multiple letters) [6] Cmaj. 160: 1697-1699. PMID 10410629  1
1999 Trachtenberg J, Crook J, Tannock IF. Prostate cancer: 11. Alternative approaches and the future of treatment. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 160: 528-34. PMID 10081469  1
1998 Shapiro JD, Phillips KA, Tannock IF. More pharmaceutical company influence? [3] Australian and New Zealand Journal of Medicine. 28: 675. PMID 9847969 DOI: 10.1111/j.1445-5994.1998.tb00676.x  1
1998 Dowling AJ, Tannock IF. Systemic treatment for prostate cancer Cancer Treatment Reviews. 24: 283-301. PMID 9805508 DOI: 10.1016/S0305-7372(98)90062-7  1
1998 Tannock IF, Warr DG. Unconventional therapies for cancer: A refuge from the rules of evidence? Cmaj. 159: 801-802. PMID 9805028  1
1998 Michael M, Tannock IF, Czaykowski PM, Moore MJ. Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: The Princess Margaret Hospital experience British Journal of Urology. 82: 366-372. PMID 9772872 DOI: 10.1046/j.1464-410X.1998.00746.x  1
1998 Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy Journal of Clinical Oncology. 16: 3179-3190. PMID 9738590  1
1998 Michael M, Tannock IF. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment Cmaj. 158: 1727-1734. PMID 9676550  1
1998 Yamagata M, Hasuda K, Stamato T, Tannock IF. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. British Journal of Cancer. 77: 1726-31. PMID 9667639 DOI: 10.1038/Bjc.1998.289  1
1998 Siu LL, Czaykowski PM, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx Journal of Clinical Oncology. 16: 2514-2521. PMID 9667272  1
1998 Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A, Tannock IF. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized tial with palliative end points Journal of Clinical Oncology. 16: 2272-2279. PMID 9626231 DOI: 10.1200/Jco.1998.16.6.2272  1
1998 Tannock IF. Conventional cancer therapy: Promise broken or promise delayed? Lancet. 351. PMID 9606361 DOI: 10.1016/S0140-6736(98)90327-0  1
1998 Lee AH, Tannock IF. Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells Cancer Research. 58: 1901-1908. PMID 9581831  1
1997 Siu LL, Tannock IF. Chemotherapy dose escalation: Case unproven Journal of Clinical Oncology. 15: 2765-2768. PMID 9256117  1
1997 Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study Journal of Clinical Oncology. 15: 2564-2569. PMID 9215826 DOI: 10.1200/Jco.1997.15.7.2564  1
1997 Vukovic V, Tannock IF. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. British Journal of Cancer. 75: 1167-72. PMID 9099966  1
1996 Moore MJ, Tannock IF. Overview of Canadian trials in hormonally resistant prostate cancer Seminars in Oncology. 23: 15-19. PMID 8996579  1
1996 Tannock IF. Treatment of cancer with radiation and drugs Journal of Clinical Oncology. 14: 3156-3174. PMID 8955662  1
1996 Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation Journal of Clinical Oncology. 14: 2901-2907. PMID 8918486 DOI: 10.1200/Jco.1996.14.11.2901  1
1996 Yamagata M, Tannock IF. The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. British Journal of Cancer. 73: 1328-34. PMID 8645575 DOI: 10.1038/Bjc.1996.254  1
1996 Tannock IF. False-positive results in clinical trials: Multiple significance tests and the problem of unreported comparisons Journal of the National Cancer Institute. 88: 206-207. PMID 8632495 DOI: 10.1093/Jnci/88.3-4.206  1
1996 Liu FF, Diep K, Tannock IF, Hill RP. The effect of heat on Na+/H+ antiport function and survival in mammalian cells International Journal of Radiation Oncology Biology Physics. 34: 623-634. PMID 8621287 DOI: 10.1016/0360-3016(95)02116-7  1
1995 Wood PJ, Sansom JM, Newell K, Tannock IF, Stratford IJ. Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore nigericin International Journal of Cancer. 60: 264-268. PMID 7829226 DOI: 10.1002/ijc.2910600222  1
1995 Tannock IF. The recruitment of patients into clinical trials British Journal of Cancer. 71: 1134-1135. PMID 7779700 DOI: 10.1038/bjc.1995.221  1
1995 Doyle C, Tannock IF. Adjuvant radiation or systemic therapy for renal cell carcinoma: A brief review Urologic Oncology: Seminars and Original Investigations. 1: 161-165. DOI: 10.1016/1078-1439(95)00055-0  1
1994 Rajagopal S, Goodman PJ, Tannock IF. Adjuvant chemotherapy for breast cancer: Discordance between physicians' perception of benefit and the results of clinical trials Journal of Clinical Oncology. 12: 1296-1304. PMID 8201392  1
1994 Luo J, Tannock IF. Inhibition of the regulation of intracellular pH: Potential of 5-(N, N-hexamethylene) amiloride in tumour-selective therapy British Journal of Cancer. 70: 617-624. PMID 7917906 DOI: 10.1038/bjc.1994.360  1
1994 Hasuda K, Lee C, Tannock IF. Antitumor activity of nigericin and 5-(N-ethyl-N-isopropyl)amiloride: An approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH Oncology Research. 6: 259-268. PMID 7865901  1
1994 Tannock IF. New perspectives in combined radiotherapy and chemotherapy treatment Lung Cancer. 10. PMID 7522114 DOI: 10.1016/0169-5002(94)91665-9  1
1994 Oza AM, Tannock IF. Clinical relevance of breast cancer biology Hematology/Oncology Clinics of North America. 8: 1-14. PMID 7512087  1
1993 Tannock IF, Erwin TJ, Stewart DJ, Fontaine B, Gupta S. Phase II multicenter study of epirubicin for hormone-resistant prostatic cancer with measurable soft tissue disease. American Journal of Clinical Oncology. 16: 156-8. PMID 8452110 DOI: 10.1097/00000421-199304000-00016  1
1993 Boyer MJ, Tannock IF. Lysosomes, lysosomal enzymes, and cancer Advances in Cancer Research. 60: 269-291. PMID 8417501 DOI: 10.1016/S0065-230X(08)60828-3  1
1993 Maidorn RP, Cragoe EJ, Tannock IF. Therapeutic potential of analogues of amiloride: Inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy British Journal of Cancer. 67: 297-303. PMID 8381657 DOI: 10.1038/bjc.1993.56  1
1993 Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma Journal of Urology. 150: 1131-1134. PMID 8371371 DOI: 10.1016/S0022-5347(17)35706-3  1
1993 Karuri AR, Dobrowsky E, Tannock IF. Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment British Journal of Cancer. 68: 1080-1087. PMID 8260358 DOI: 10.1038/bjc.1993.485  1
1993 Boyer MJ, Barnard M, Hedley DW, Tannock IF. Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours British Journal of Cancer. 68: 890-897. PMID 8217605 DOI: 10.1038/Bjc.1993.451  1
1992 Tannock IF, Cummings BJ, Pfister DG, Harrison LB, Strong EW, Bosl GJ. Neoadjuvant chemotherapy in head and neck cancer: No way to preserve a larynx [1] Journal of Clinical Oncology. 10: 343-345. PMID 1732435 DOI: 10.1200/JCO.1992.10.2.343  1
1992 Tannock IF, Belanger D. Use of a physician-directed questionnaire to define a consensus about management of breast cancer: implications for assessing costs and benefits of treatment Journal of the National Cancer Institute. Monographs. 137-142. PMID 1627419  1
1992 De Bellefeuille C, Morrison CA, Tannock IF. The fate of abstracts submitted to a cancer meeting: Factors which influence presentation and subsequent publication Annals of Oncology. 3: 187-191. PMID 1586615  1
1992 Tannock IF. Some problems related to the design and analysis of clinical trials International Journal of Radiation Oncology, Biology, Physics. 22: 881-885. PMID 1555980 DOI: 10.1016/0360-3016(92)90783-E  1
1992 Tannock IF. Potential for therapeutic gain from combined-modality treatment Frontiers of Radiation Therapy and Oncology. 26: 1-15. PMID 1511912  1
1992 Tannock IF. Assessment of study design in clinical trials for bladder cancer Urologic Clinics of North America. 19: 655-662. PMID 1441023  1
1992 Oza AM, Rawlings G, Tannock IF. Axillary nodes dissection in breast cancer Lancet. 340: 246-247. PMID 1353173  1
1992 Boyer MJ, Tannock IF. Regulation of Intracellular pH in Tumor Microenvironmental Conditions Cancer Research. 52: 4441-4447. PMID 1322790  1
1991 Dobrowsky E, Newell K, Tannock IF. The potential of lactate and succinate to kill nutrient deprived tumor cells by intracellular acidification International Journal of Radiation Oncology, Biology, Physics. 20: 275-279. PMID 1991688 DOI: 10.1016/0360-3016(91)90104-C  1
1991 Belanger D, Moore M, Tannock I. How American oncologists treat breast cancer: An assessment of the influence of clinical trials Journal of Clinical Oncology. 9: 7-16. PMID 1985172 DOI: 10.1200/JCO.1991.9.1.7  1
1991 Luk CK, Tannock IF. Evaluation of the probability of spontaneous transfer of drug resistance between cells in culture In Vitro Cellular and Developmental Biology - Animal. 27: 245-248. PMID 1903383 DOI: 10.1007/Bf02630924  1
1991 Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy Journal of Clinical Oncology. 9: 509-524. PMID 1705581  1
1990 Tannock IF. The current status of adjuvant chemotherapy for bladder cancer Seminars in Urology. 8: 291-297. PMID 2284534  1
1990 Moore MJ, O’Sullivan B, Tannock IF. Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues? British Journal of Cancer. 62: 988-991. PMID 2257231 DOI: 10.1038/Bjc.1990.422  1
1990 Tannock IF. The reporting of trials of adjuvant therapy for breast cancer Journal of Clinical Oncology. 8: 1923-1924. PMID 2230881  1
1990 Tannock IF. Endpoints of clinical trials in invasive bladder cancer Seminars in Oncology. 17: 619-627. PMID 2218575  1
1990 Tannock IF. Endpoints of clinical trials for muscle-invasive bladder cancer Progress in Clinical and Biological Research. 353: 65-74. PMID 2217428  1
1990 Quirt IC, Tannock IF. Interleukin-2 for metastatic melanoma: Treating polyuria with insulin? Journal of Clinical Oncology. 8: 1125-1127. PMID 2193116  1
1990 Tannock IF, Boyer M. When is a cancer treatment worthwhile? New England Journal of Medicine. 323: 989-990. PMID 2169589 DOI: 10.1056/Nejm199010043231410  1
1990 Tannock IF. Management of breast and prostate cancer: how does quality of life enter the equation? Oncology (Williston Park, N.Y.). 4: 149-156; discussion . PMID 2143400  1
1990 Luk CK, Veinot-drebot L, Tjan E, Tannock IF. Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines Journal of the National Cancer Institute. 82: 684-692. PMID 1969493 DOI: 10.1093/Jnci/82.8.684  1
1990 Tannock IF. Cancer biology: Editorial overview Current Opinion in Oncology. 2: 119-120.  1
1989 Newell KJ, Tannock IF. Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone. Cancer Research. 49: 4477-82. PMID 2743336  1
1989 Tannock IF. Combined modality treatment with radiotherapy and chemotherapy Radiotherapy and Oncology. 16: 83-101. PMID 2687956 DOI: 10.1016/0167-8140(89)90025-X  1
1989 Luk CK, Tannock IF. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines Journal of the National Cancer Institute. 81: 55-59. PMID 2642304 DOI: 10.1093/Jnci/81.1.55  1
1989 Tannock IF, Rotin D. Acid pH in Tumors and Its Potential for Therapeutic Exploitation Cancer Research. 49: 4373-4384. PMID 2545340  1
1988 Tannock IF, Rotin D. Keynote Address: Mechanisms of interaction between radiation and drugs with potential for improvements in therapy Nci Monographs. 77-83. PMID 3352792  1
1988 Tannock IF. Analysis of trials using chemotherapy for metastatic bladder cancer Progress in Clinical and Biological Research. 260: 487-498. PMID 3283769  1
1988 Luk CK, Tannock IF. Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: A model for studying host effects on apparent drug resistance British Journal of Cancer. 58: 133-138. PMID 3166902 DOI: 10.1038/bjc.1988.179  1
1988 Moore MJ, O'Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer Journal of Clinical Oncology. 6: 1736-1745. PMID 3054004 DOI: 10.1200/Jco.1988.6.11.1736  1
1987 Tannock IF. Toxicity of 5-fluorouracil for aerobic and hypoxic cells in two murine tumours Cancer Chemotherapy and Pharmacology. 19: 53-56. PMID 3815727 DOI: 10.1007/Bf00296256  1
1987 Tannock IF. Treating the patient, not just the cancer New England Journal of Medicine. 317: 1534-1535. PMID 3683488 DOI: 10.1056/Nejm198712103172409  1
1986 Tannock IF, Steele D, Roberts J. Influence of reduced concentration of l-glutamine on growth and viability of cells in monolayer, in spheroids, and in experimental tumours British Journal of Cancer. 54: 733-741. PMID 3801270 DOI: 10.1038/bjc.1986.234  1
1986 Erlichman C, Tannock IF. Growth and characterization of multicellular tumor spheroids of human bladder carcinoma origin In Vitro Cellular &Amp; Developmental Biology. 22: 449-456. PMID 3733640 DOI: 10.1007/BF02623445  1
1986 Tannock IF, Kopelyan I. Variation of pO2 in the growth medium of spheroids: Interaction with glucose to influence spheroid growth and necrosis British Journal of Cancer. 53: 823-827. PMID 3718836 DOI: 10.1038/bjc.1986.139  1
1986 Rotin D, Tannock IF, Robinson B. Influence of Hypoxia and an Acidic Environment on the Metabolism and Viability of Cultured Cells: Potential Implications for Cell Death in Tumors Cancer Research. 46: 2821-2826. PMID 3698008  1
1986 Tannock IF, Browman G. Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer Journal of Clinical Oncology. 4: 1121-1126. PMID 3522819  1
1986 Tannock IF, Kopelyan I. Influence of Glucose Concentration on Growth and Formation of Necrosis in Spheroids Derived from a Human Bladder Cancer Cell Line Cancer Research. 46: 3105-3110. PMID 3516390  1
1986 Tannock IF. Experimental chemotherapy and concepts related to the cell cycle International Journal of Radiation Biology. 49: 335-355. PMID 3510996 DOI: 10.1080/09553008514552581  1
1985 Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? Journal of Clinical Oncology. 3: 1013-1021. PMID 3894584  1
1985 Tannock IF, Evans WK. Failure of 5-day vinblastine infusion in the treatment of patients with renal cell carcinoma Cancer Treatment Reports. 69: 227-228. PMID 3882231  1
1985 Bell DR, Tannock IF, Boyd NF. Quality of life measurement in breast cancer patients British Journal of Cancer. 51: 577-580. PMID 3838481 DOI: 10.1038/bjc.1985.81  1
1984 Tannock I, Choo B, Buick R. The radiation response of human bladder cancer assessed in vitro or as xenografts in immune-deprived mice International Journal of Radiation Oncology, Biology, Physics. 10: 1897-1902. PMID 6490419 DOI: 10.1016/0360-3016(84)90269-4  1
1984 Rotin D, Tannock IF. The effect of the drug lonidamine on chinese hamster ovary cells in vitro and on experimental tumors International Journal of Radiation Oncology, Biology, Physics. 10: 1595-1598. PMID 6480446 DOI: 10.1016/0360-3016(84)90509-1  1
1984 Tannock IF. Chemotherapy for head and neck cancer Journal of Otolaryngology. 13: 99-104. PMID 6202878  1
1984 Buick RN, Selby P, Tannock IF. In vitro tests for predicting response to chemotherapy Cancer Bulletin. 36: 179-184.  1
1983 Tannock IF, Gospodarowicz M, Evans WK. Chemotherapy for metastatic transitional carcinoma of the urinary tract. A prospective trial of methotrexate, Adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure Cancer. 51: 216-219. PMID 6681591 DOI: 10.1002/1097-0142(19830115)51:2<216::Aid-Cncr2820510208>3.0.Co;2-I  1
1983 Rauth AM, Mohindra JK, Tannock IF. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Research. 43: 4154-8. PMID 6409398  1
1983 Tannock IF. Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract Cancer Treatment Reports. 67: 503-504. PMID 6406061 DOI: 10.1016/S0022-5347(17)50271-2  1
1983 Tannock IF. Biology of tumor growth Hospital Practice. 18: 81-93. PMID 6404785 DOI: 10.1080/21548331.1983.11702514  1
1983 Tannock IF, Guttman P, Rauth AM. Failure of 2-deoxy-D-glucose and 5-thio-D-glucose to kill hypoxic cells of two murine tumors. Cancer Research. 43: 980-3. PMID 6337709  1
1983 Selby P, Buick RN, Tannock I. A critical appraisal of the 'human tumor stem-cell assay' New England Journal of Medicine. 308: 129-134. PMID 6336820 DOI: 10.1056/Nejm198301203080304  1
1982 Erlichman C, Vidgen D, Tannock IF. The effect of adriamycin (ADR) on a human bladder cell line (MGH-U1) grown as a monolayer, as spheroids and in immune-deprived mice Proceedings of the American Association For Cancer Research. 669.  1
1980 Tannock IF. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: Cyclophosphamide and BCNU British Journal of Cancer. 42: 871-880. PMID 7459221 DOI: 10.1038/bjc.1980.335  1
1980 Tannock IF. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: Methotrexate, 5-fluorouracil and adriamycin British Journal of Cancer. 42: 861-870. PMID 7459220 DOI: 10.1038/bjc.1980.334  1
1980 Tannock IF, Sutherland DJ. Chemotherapy for adenocystic carcinoma. Cancer. 46: 452-4. PMID 6249480 DOI: 10.1002/1097-0142(19800801)46:3<452::Aid-Cncr2820460305>3.0.Co;2-Z  1
1979 Tannock IF. Responsibility in advertising: an oncologist's view New England Journal of Medicine. 301: 1004. PMID 492218  1
1979 Tannock IF. Chemotherapy for hypoxic tumor cells: Metronidazole and misonidazole in combination with conventional anti-cancer drugs Proceedings of the American Association For Cancer Research 1
1972 Tannock IF. Oxygen diffusion and the distribution of cellular radiosensitivity in tumours British Journal of Radiology. 45: 515-524. PMID 5067983  1
1972 Tannock IF, Suit HD, Marshall N. Vitamin a and the radiation response of experimental tumors: An immune-mediated effect Journal of the National Cancer Institute. 48: 731-741. PMID 5058972 DOI: 10.1093/jnci/48.3.731  1
1972 Tannock IF, Hayashi S. The Proliferation of Capillary Endothelial Cells Cancer Research. 32: 77-82. PMID 5007690  1
1972 Tannock IF, Marshall N, Van Putten LM. An attempt at selective chemotherapy of hypoxic cells. Triethylenemelamine and irradiation of a C3H mouse mammary tumour European Journal of Cancer (1965). 8: 501-507. PMID 4651785 DOI: 10.1016/0014-2964(72)90101-6  1
1972 Jurin M, Tannock IF. Influence of vitamin A on immunological response Immunology. 23: 283-287. PMID 4609898  1
1970 Burns FJ, Tannock IF. On the existence of a G 0 -phase in the cell cycle Cell and Tissue Kinetics. 3: 321-334. PMID 5523059 DOI: 10.1111/j.1365-2184.1970.tb00340.x  1
1970 Gillette EL, Withers HR, Tannock IF. The age sensitivity of epithelial cells of mouse small intestine Radiology. 96: 639-643. PMID 5456320  1
1970 Tannock IF, Steel GG. Tumor growth and cell kinetics in chronically hypoxic animals Journal of the National Cancer Institute. 45: 123-133. PMID 5449210  1
1970 Tannock IF. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor Cancer Research. 30: 2470-2476. PMID 4097429  1
1969 Tannock IF. A Comparison of Cell Proliferation Parameters in Solid and Ascites Ehrlich Tumors Cancer Research. 29: 1527-1534. PMID 5807228  1
1969 Tannock IF, Steel GG. Quantitative techniques for study of the anatomy and function of small blood vessels in tumors Journal of the National Cancer Institute. 42: 771-782. PMID 4182071 DOI: 10.1093/jnci/42.5.771  1
1968 Tannock IF. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour British Journal of Cancer. 22: 258-273. PMID 5660132 DOI: 10.1038/bjc.1968.34  1
1967 Tannock IF. A comparison of the relative efficiencies of various metaphase arrest agents Experimental Cell Research. 47: 345-356.  1
Show low-probability matches.